Floxin (ofloxacin) is a broad-spectrum fluoroquinolone antibiotic indicated for the treatment of adults with serious bacterial infections. As a second-generation quinolone, it demonstrates potent bactericidal activity against both Gram-positive and Gram-negative pathogens through inhibition of bacterial DNA gyrase and topoisomerase IV. Clinically validated for efficacy in complicated urinary tract infections, prostatitis, lower respiratory tract infections, and skin structure infections, Floxin represents a critical therapeutic option when first-line agents are contraindicated or ineffective. Its well-characterized pharmacokinetic profile ensures reliable tissue penetration and predictable serum concentrations when administered according to established guidelines.

Features

• Active ingredient: ofloxacin 200mg, 300mg, or 400mg tablets
• Mechanism: inhibits bacterial DNA gyrase and topoisomerase IV enzymes
• Spectrum: broad activity against Gram-positive and Gram-negative aerobes
• Bioavailability: approximately 98% following oral administration
• Half-life: 4–8 hours in adults with normal renal function
• Excretion: primarily renal (80–90% unchanged)

Benefits

• Rapid bactericidal action reduces bacterial load within 24–48 hours of initiation
• Excellent tissue penetration achieves therapeutic concentrations at infection sites
• Convenient twice-daily dosing supports adherence and steady-state pharmacokinetics
• Demonstrated efficacy against multidrug-resistant pathogens in validated indications
• Well-established safety profile with extensive clinical documentation
• Oral formulation avoids IV administration in appropriate clinical scenarios

Common use

Floxin is indicated for the treatment of adults (18 years and older) with infections caused by susceptible strains of designated microorganisms. Primary indications include complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, and Enterobacter cloacae. It is also approved for chronic bacterial prostatitis caused by E. coli, community-acquired pneumonia due to Streptococcus pneumoniae or Haemophilus influenzae, and uncomplicated skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Off-label use may occur in certain nosocomial infections when susceptibility is confirmed.

Dosage and direction

The recommended dosage varies by indication and renal function. For complicated urinary tract infections: 200mg every 12 hours for 10 days. For chronic bacterial prostatitis: 300mg every 12 hours for 6 weeks. For community-acquired pneumonia: 400mg every 12 hours for 10 days. For skin infections: 400mg every 12 hours for 10 days. Dosage adjustment is required for patients with creatinine clearance below 50 mL/min. Tablets should be swallowed whole with water, and may be taken with or without food. Administration with dairy products or calcium-fortified juices should be avoided as they may impair absorption. Complete the full course of therapy even if symptoms improve earlier.

Precautions

Fluoroquinolones, including Floxin, have been associated with disabling and potentially irreversible serious adverse reactions. Tendon inflammation or rupture may occur during or after therapy, particularly in elderly patients, those taking corticosteroids, and organ transplant recipients. Peripheral neuropathy characterized by pain, burning, tingling, numbness, and/or weakness has been reported and may be irreversible. Central nervous system effects including seizures, increased intracranial pressure, and psychosis have been observed. Exacerbation of myasthenia gravis may occur. Photosensitivity reactions may manifest as exaggerated sunburn reactions; patients should avoid excessive sunlight and ultraviolet light exposure. Clostridium difficile-associated diarrhea may range from mild to life-threatening. Regular assessment of renal and hepatic function is recommended during extended therapy.

Contraindications

Floxin is contraindicated in patients with known hypersensitivity to ofloxacin, other quinolones, or any component of the formulation. Concomitant administration with tizanidine is contraindicated due to potentiated hypotensive and sedative effects. Use is contraindicated in patients with history of tendon disorders related to fluoroquinolone administration. The drug is not recommended in patients with known prolongation of the QT interval, uncorrected hypokalemia, or those taking Class IA or III antiarrhythmic agents. Safety and effectiveness in pediatric patients, adolescents under 18 years, and pregnant women have not been established.

Possible side effect

Common adverse reactions (≥1%) include nausea (3–10%), headache (3–9%), insomnia (3–7%), dizziness (1–5%), and diarrhea (1–4%). Less frequent reactions include photosensitivity (≤2%), tendon pain (≤1%), and vaginal candidiasis (1–3%). Serious adverse reactions include tendon rupture (<0.1%), peripheral neuropathy (<0.1%), QT prolongation (<0.1%), hepatotoxicity (<0.1%), and blood dyscrasias. Psychiatric reactions including anxiety, agitation, and confusion have been reported. Hypersensitivity reactions ranging from rash to anaphylaxis may occur. Crystalluria may develop, particularly in alkaline urine or dehydrated states.

Drug interaction

Antacids containing magnesium, aluminum, or calcium; sucralfate; iron preparations; and zinc supplements significantly reduce absorption—administer Floxin at least 2 hours before or 4 hours after these products. NSAIDs may increase the risk of CNS stimulation and seizures. Probenecid interferes with renal tubular secretion and may increase ofloxacin concentrations. Warfarin monitoring is recommended due to potential enhancement of anticoagulant effect. QT prolongation may be additive with other drugs that prolong the QT interval. Corticosteroids may increase the risk of tendon rupture. Theophylline clearance may be decreased, requiring monitoring of serum concentrations.

Missed dose

If a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next dose, skip the missed dose and continue with the regular dosing schedule. Do not double the dose to make up for a missed one. Maintaining consistent antibiotic concentrations is important for efficacy and resistance prevention. Patients should be instructed to set reminders and establish a routine dosing schedule to maximize adherence.

Overdose

Symptoms of overdose may include dizziness, nausea, vomiting, gastric irritation, and CNS excitation including seizures. Renal crystalluria may occur with massive overdose. ECG monitoring is recommended due to potential QT prolongation. Management is supportive with careful observation and maintenance of hydration. Hemodialysis removes approximately 20–30% of the drug and may be considered in severe cases. There is no specific antidote. Contact a poison control center for latest guidance.

Storage

Store at controlled room temperature 20°–25°C (68°–77°F) with excursions permitted between 15°–30°C (59°–86°F). Keep in the original container with the lid tightly closed. Protect from light and excessive moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Do not transfer tablets to other containers as this may affect stability. Discard any unused medication properly according to local regulations.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Floxin is a prescription medication that should be used only under the supervision of a qualified healthcare professional. The prescribing physician should be consulted for diagnosis and treatment decisions. Individual results may vary. Serious side effects may occur, and patients should report any unusual symptoms to their healthcare provider immediately. This summary is not exhaustive; please refer to the full prescribing information for complete details.

Reviews

Clinical studies demonstrate Floxin achieves clinical cure rates of 85–95% in complicated urinary tract infections and 80–90% in respiratory infections when caused by susceptible organisms. In comparative trials, it has shown equivalent efficacy to other fluoroquinolones with a similar safety profile. Post-marketing surveillance indicates satisfactory patient tolerance when prescribed appropriately. Many infectious disease specialists value its reliable activity against common uropathogens and respiratory pathogens. However, increasing bacterial resistance patterns necessitate culture and susceptibility testing before use when possible. The drug remains an important option in the antimicrobial arsenal despite newer agents due to its established efficacy and favorable pharmacokinetics.